A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 33/00 (2006.01) A61K 31/00 (2006.01) A61K 31/07 (2006.01) A61K 31/12 (2006.01) A61K 31/13 (2006.01) A61K 31/135 (2006.01) A61K 31/19 (2006.01) A61K 31/41 (2006.01) A61K 31/47 (2006.01) A61K 31/495 (2006.01) A61K 31/54 (2006.01)
Patent
CA 2135070
The invention relates to the administration of guanylate cyclase inhibitors, such as methylene blue, for the treatment of septic shock, cardiogenic shock, hypovolemic shock, obstructive shock, neuropathic shock and hypotension caused by excessive doses of nitrovasodilators. The invention also relates to the use of other redox dyes, such as toluidine blue, neutral red, tetrazolium salts, chloranil and dichlorophenolindophenol for the treatment of shock.
L'invention se rapporte à l'administration d'inhibiteurs de guanylate cyclase, tels que le bleu de méthylène, destinés au traitement du choc septique, du choc cardiogène, du choc hypovolémique, du choc obstructif, du choc névropathique et de l'hypotension, provoqués par des doses excessives de nitrovasodilatateurs. L'invention se rapporte également à l'utilisation d'autres teintes redox, telles que le bleu toluidine, le rouge neutre, les sels de tétrazole, le chloranile et le dichlorophénolindophénol dans le traitement d'états de choc.
Loscalzo Joseph
Stamler Jonathan
Smart & Biggar
The Brigham And Women's Hospital
LandOfFree
Use of guanylate cyclase inhibitors in the treatment of shock does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of guanylate cyclase inhibitors in the treatment of shock, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of guanylate cyclase inhibitors in the treatment of shock will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2023509